secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002696
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa outlines 2024 milestones: Fast Track for MRT-2359, MRT-6160 Phase 1, cash into H1 2026
--------------------------------------------------------------------------------

- FDA Fast Track Designation for MRT-2359 in previously treated metastatic SCLC with L-MYC or N-MYC expression.
- RP2D for MRT-2359 Phase 1/2 trial in MYC-driven solid tumors expected Q2 2024; new dose schedule initiated.
- MRT-6160 (VAV1-directed MGD) IND submission H1 2024, Phase 1 SAD/MAD study in healthy volunteers mid-2024.
- Cash runway into H1 2026; NEK7 development candidate nomination Q1 2024, CDK2 candidate in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/0000950170-24-002696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024002696/glue-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer